All In Biotech

Drug Trial Radar · NCT02697734

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

73

Actual

Start

Oct 3, 2016

Primary completion

Jun 19, 2019

Study completion Dec 31, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.

Conditions

  • Cushing's Disease

Interventions

  • osilodrostatDrug

    In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.

  • osilodrostat PlaceboDrug

    Matching Placebo in the form of filmcoated tablets for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Randomized Participants With a Complete ResponseTime frame: at Week 12

Locations

36 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Colorado Endocrinology Clinical Trials Unit

    Aurora, Colorado

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Columbia University Medical Center New York Presbyterian Neuroendocrine Unit

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Oregon Health and Science University SC LCI699C2301

    Portland, Oregon

  • University of Pennsylvania Medical Center University of Pennsylvania

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    San Pedro, San Jose, Costa Rica, Costa Rica

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Krakow, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Warsaw, Masovian Voivodeship, Poland

  • Novartis Investigative Site

    Porto, Portugal

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Andalusia, Spain

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    A Coruña, Galicia, Spain

  • Novartis Investigative Site

    Alzira, Valencia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Lucerne, Switzerland

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Bangkok, THA, Thailand

  • Novartis Investigative Site

    Istanbul, Turkey (Türkiye)

  • Novartis Investigative Site

    Kocaeli, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.